Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance

Abstract Acquired resistance to osimertinib is inevitable and heterogeneous despite its documented efficacy against EGFR‐mutated non‐small cell lung cancer (NSCLC). Subsequent therapeutic options assume the dominant form of the resistance mechanism; however, the more rare oncogenic driver, NTRK1 fus...

Full description

Bibliographic Details
Main Authors: Jiao‐Li Wang, Liu‐sheng Wang, Jun‐qi Zhu, Jie Ren, Di Wang, Man Luo
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:Respirology Case Reports
Subjects:
EGFR‐TKI acquired resistance
non‐small cell lung cancer (NSCLC)
NTRK fusion
osimertinib rechallenge
Online Access:https://doi.org/10.1002/rcr2.1054

Similar Items

Similar Items